Grid Therapeutics is a biotech company based on the innovative science first developed by Edward F. Patz, Jr. MD and his team of scientists at Duke University Medical Center. Located in Durham, North Carolina, Grid is developing the first human derived targeted immunotherapy for cancer. The antibody was discovered in exceptional outcome early stage lung cancer patients and was isolated from patient's B-cells using state of the art molecular genomic techniques. 'GT103', the company's lead asset, is expected to enter a first-in-man Phase 1 clinical trial in advanced-stage solid tumor patients in early 2019.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
09/14/17	undisclosed	Series A	Duke University Longview International	undisclosed
04/18/18	undisclosed	Series B	Jeffery Heyman Milestone Holdings Paul Funk	undisclosed